RenovaCare products are under development and not approved for sale in the United States.
Results may vary from person to person.

RenovaCare products are under development and not approved for sale in the United States.
Results may vary from person to person.

Corporate Q&A

You may call RenovaCare, Inc. toll-free using the phone number at the bottom of each web page: 1-888-398-0202, or you may send an email using our contact form.

Yes, RenovaCare, Inc. is a next-generation developer of medical devices, autologous stem cell therapies, and wound care products, publicly traded under the ticker symbol: RCAR on the OTCQB exchange in the USA.

Please see below for the following options: RCAR common shares can only be purchased through a registered investment advisor, stockbroker, or financial services firm and/or bank that provides share brokerage services. Shares may not be purchased directly through the Company at this time. Should you or your broker require additional information, kindly contact RenovaCare Investor Relations at 1-888-398-0202 or by using our website contact form to reach us. Investor education information is available through the Securities and Exchange Commission’s Office of Investor Education at, or on our SEC Filings page via:

RenovaCare’s transfer agent is Worldwide Stock Transfer, LLC. The transfer agent is able to assist investors who have misplaced, lost, or destroyed share certificates. Should you or your broker need to get in touch with RenovaCare’s transfer agent, kindly refer to the contact information below:

Worldwide Stock Transfer, LLC
One University Plaza, Suite 505
Hackensack, NJ 07601
Phone: (201) 820-2008
Fax: (201) 820-2010

RenovaCare’s quarterly fiscal reporting periods are as listed below:

Q1 January 1 through March 31
Q2 April 1 through June 30
Q3 July 1 through September 30
Q4 October 1 through December 31
RenovaCare’s fiscal year ends December 31

RenovaCare, Inc. was first incorporated as American Alliance Corporation. in the State of Nevada, effective June 30, 1997. The new Company name became effective on January 7, 2014.

RenovaCare routinely files financial reports and discloses financial information as per legal requirements stipulated by the Securities Exchange Commission (SEC). The Company’s filings may be viewed on this web site’s ‘SEC Filings’ section or at the SEC web site at

Technology Q&A

The CellMist™ System is an innovative investigational medical treatment for processing and spraying a patient’s own stem cells onto wounds for rapid healing.

The CellMist™ System is comprised of two primary components:

  • The CellMist™ Solution
    A liquid suspension containing a patient’s own stem cells which are isolated from a small sample of their skin, using a patented process.
  • The SkinGun™
    A patented investigational medical device which gently sprays the CellMist™ Solution on to a wound site for rapid healing.

Once sprayed onto the wound site, the patient’s stem cells contained in the CellMist™ Solution go to work, naturally and rapidly regenerating damaged skin.

The CellMist™ System replaces traditional skin grafts, harvested through painful surgery to remove significant portions of skin from the donor’s body.  These graft surgeries create large secondary wounds. The CellMist™ System requires only a postage stamp-sized sample of donor skin.

Our patented SkinGun™ is an investigational spray device specially designed to deliver the CellMist™ Solution and its regenerative stem cells to heal burns and wounds.

Stem cells are delicate and can be easily damaged by conventional spray methods.  These pumps use mechanical compression, generating turbulent forces which can thrash and damage the cells.

In contrast, the SkinGun™ is an ultra-gentle sprayer, which delicately carries the patient’s own stem cells to wound sites.  We make use of a novel positive-pressure system engineered to avoid violent forces.

The CellMist™ System sprays a patient’s own stem cells onto wounds, naturally regenerating skin to heal traumatic wounds quicker than traditional therapies.

First, a patient’s cells are liberated from a small sample of skin, often as little as a postage stamp.  These naturally potent cells are collected in a water-based liquid called the CellMist™ Solution.

Next, the CellMist™ Solution is sprayed gently onto the wounded area using our patented investigational SkinGun™.

This procedure takes as little as 90 minutes from start to finish. In some cases, patients can leave the hospital within a few days, rather than the many weeks required by alternative treatments.

The CellMist™ System has been used in experimental procedures to treat severe second-degree burns.

Our future target markets include chronic wounds, vitiligo (areas of unpigmented skin), scars, and other skin disorders, which collectively account for a $45 billion market and 143 million patients.

The CellMist™ System is under development and has only been used in experimental protocols on a very limited basis.  Our technologies are not currently available for use or treatment in the United States.

RenovaCare’s Solution Spray Deposition Device was designed to meet a specific clinical need. Liquid spraying, such as saline solution spraying to cleanse a wound, to irrigate a wound, or to maintain a moist wound environment is clinically desirable in surgery. While saline and other wound-wetting solutions’ distribution over burns and other wounds is typically performed by pouring the liquid or squirting with a standard syringe, RenovaCare has developed a device that sprays gently and evenly over a large wound area.

Sign Up for Investor Alerts